- Home
- IGD vs AQST Comparison
IGD vs AQST Comparison
Compare IGD & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IGD | AQST |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 516.6M | 529.4M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | IGD | AQST |
|---|---|---|
| Price | $6.60 | $4.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 244.9K | ★ 1.9M |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 9.15% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | N/A | $10.08 |
| Revenue Next Year | N/A | $49.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $5.58 | $2.94 |
| 52 Week High | $6.59 | $7.55 |
Technical Indicators
Market Signals| Indicator | IGD | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 66.78 | 64.01 |
| Support Level | $5.62 | $3.99 |
| Resistance Level | $6.59 | $5.10 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 88.46 | 92.44 |
Price Performance
Historical ComparisonAbout IGD Voya Global Equity Dividend and Premium Opportunity Fund
Voya Global Equity Dividend and Premium Opportunity Fund are a United States-based diversified, closed-end Fund. The primary objective of the Fund is to seek to provide investors with a high level of income from a portfolio of common stocks with historically attractive dividend yields and premiums from call option writing. The secondary investment objective of the company is capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in a portfolio of common stocks of dividend-paying companies located throughout the world.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.